These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

502 related items for PubMed ID: 22370297

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Anabolic therapy in glucocorticoid-induced osteoporosis.
    Sambrook PN.
    N Engl J Med; 2007 Nov 15; 357(20):2084-6. PubMed ID: 18003966
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT, Christensen PM, Ejersted C, Langdahl BL.
    Basic Clin Pharmacol Toxicol; 2004 Jun 15; 94(6):260-70. PubMed ID: 15228497
    [Abstract] [Full Text] [Related]

  • 10. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.
    Bone; 2006 Dec 15; 39(6):1268-75. PubMed ID: 16884968
    [Abstract] [Full Text] [Related]

  • 11. Active comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from the Hispanic and non-Hispanic cohorts.
    Losada BR, Zanchetta JR, Zerbini C, Molina JF, De la Peña P, Liu CC, Smith RB, Nino AJ, Krohn K, Warner MR.
    J Clin Densitom; 2009 Dec 15; 12(1):63-70. PubMed ID: 19028124
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Anabolic therapies for osteoporosis.
    Uihlein AV, Leder BZ.
    Endocrinol Metab Clin North Am; 2012 Sep 15; 41(3):507-25. PubMed ID: 22877427
    [Abstract] [Full Text] [Related]

  • 15. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
    Burshell AL, Möricke R, Correa-Rotter R, Chen P, Warner MR, Dalsky GP, Taylor KA, Krege JH.
    Bone; 2010 Apr 15; 46(4):935-9. PubMed ID: 20060081
    [Abstract] [Full Text] [Related]

  • 16. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
    Liu H, Michaud K, Nayak S, Karpf DB, Owens DK, Garber AM.
    Arch Intern Med; 2006 Jun 12; 166(11):1209-17. PubMed ID: 16772249
    [Abstract] [Full Text] [Related]

  • 17. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Babb RR.
    N Engl J Med; 2008 Mar 20; 358(12):1302-3; author reply 1303-4. PubMed ID: 18357641
    [No Abstract] [Full Text] [Related]

  • 18. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions.
    Bultink IE, Baden M, Lems WF.
    Expert Opin Pharmacother; 2013 Feb 20; 14(2):185-97. PubMed ID: 23317448
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
    Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH.
    J Bone Miner Res; 2006 Nov 20; 21(11):1785-90. PubMed ID: 17002571
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.